

Supplementary Materials for  
**CD4<sup>+</sup> and CD8<sup>+</sup> T cells are required to prevent SARS-CoV-2 persistence in  
the nasal compartment**

Meenakshi Kar *et al.*


Corresponding author: Mehul S. Suthar, [mehul.s.suthar@emory.edu](mailto:mehul.s.suthar@emory.edu)

*Sci. Adv.* **10**, eadp2636 (2024)  
DOI: 10.1126/sciadv.adp2636

**This PDF file includes:**

Figs. S1 to S8


## SUPPLEMENTARY FIGURES





**Supplementary Figure S1- Gating strategy for flow cytometry analysis of CD4+ and CD8+ T cells at day 8 pi.** C57Bl/6 mice were infected with SARS-CoV-2 B.1.351 and spleen, lungs and nasal airway tissues were harvested at day 7 pi. Five minutes prior to euthanasia, mice were intravitaly labelled with CD45:PE (injected via the retro-orbital route). Tissues were processed to a single-cell suspension and analyzed via flow cytometry. Total cell populations were gated on (FSC-SSC), then singlets, then on Live (Ghost Dye 780). Lung infiltrating cells were identified as CD45 IV- and CD45 ex-vivo+. Tissue parenchymal

lymphocytes in case of lungs and nasal airways and total CD45+ cells in case of spleen were then gated for CD3+ cells which were further gated for CD4 and CD8+ T cells.

## ICC staining in naïve mice




**Supplementary Figure S2- Intracellular cytokine staining in naïve mice.** Naïve mice were stimulated with peptides and intracellular cytokine staining performed as described in the materials and methods.




**Supplementary Figure S3- Activation markers in CD4+ and CD8+ T cells.** Lungs, URT and spleen tissues were harvested from C57Bl/6 mice infected with SARS-CoV-2 B.1.351 at day 7 pi and analysed for activation markers CD44, KLRG1 and CD69 by flow cytometry. (A) Mean Fluorescence Intensity (MFI) (A) and representative histogram overlay plots (B) for indicated markers in CD4+ and CD8+ T cells in infected samples compared to mock in lungs, nasal airways, and spleen at day 7 pi.

**A Day 0 p.i. (Blood)**



**B Day 28 p.i.**




● Isotype control ● anti-CD4 ● anti-CD8 ● anti-CD4/CD8


**Supplementary Figure S4- CD4+ and CD8+ T cells depletion assessment at day 0 and day 28 pi in lungs and nasal airways. (A) Whole blood from mice depleted for either CD4+ T cells or CD8+ T cells or both were subjected to CD4+ and CD8+ staining to assess depletion**

efficiency as compared to the isotype control at day 0 pi. **(B)** Cells isolated from lungs, nasal airways, and whole blood at day 28 pi, were assessed for depletion efficiency as compared to the isotype control. The analysis was done on CD3<sup>+</sup> T cells which were gated on live and single CD45<sup>+</sup> lymphocytes. Cell counts depicted as insets against the respective time point and tissue type.






**Supplementary Figure S5- comparison of effect of CD8<sup>+</sup>T cell depletion using CD8 $\beta$  or CD8 $\alpha$  antibody on viral RNA levels in lungs and nasal airways at day 28 pi** Mice were either depleted using CD8 $\beta$  or CD8 $\alpha$  antibody and assessed for viral RdRp levels in **(A)** lungs and **(B)** nasal airways at day 28 pi by qRT-PCR. RNA levels were compared with individual isotype controls. n=5 mice for each group.




**Supplementary Figure S6- Quality checks for SARS-CoV-2 sequencing data. (A-C)** Fraction of the genome covered (y-axis) across different read depths (x-axis) for (A) the inoculum stock, inoculum-Vero, and inoculum-C57BL/6 controls, (B) day 28 pi CD4<sup>+</sup>/CD8<sup>+</sup> tandem T-cell depleted mouse samples, and (C) the 5 mouse isolates passaged once in VeroE6-TMPRSS2 cells. Data for each sequencing replicate are plotted and differentiated by the point

shape and line type. **(D)** The number of minor variants found at 0.5-49% in the inoculum stock and inoculum-Vero controls. **(E)** The frequency of minor variants (y-axis) found in a single stock sample versus the frequency of minor variants present in at least one inoculum stock and one inoculum-Vero sample (x-axis).



**Supplementary Figure S7- iSNV richness for each mouse isolate.** The number of high-frequency (dark gray) and low-frequency (light gray) *de novo* iSNVs (y-axis) in each mouse isolate separated by mutation type (non-coding, synonymous “syn”, nonsynonymous “nonsyn”, and nonsense).



**Supplementary Figure S8- Consensus level deletions in mouse isolates. (A)** ORF6 consensus sequences from nucleotide positions 27264-27290 across all inoculum and mouse isolate samples. Box colors represent the nucleotide found at each position. Black squares represent positions identified as a deletion. **(B)** The relative frequency of ORF6 27264-27290 deletions in other samples where it did not reach consensus levels.